News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • BOSS Zhipin Q2 revenue rose 14.1% YoY and operating income jumped 32.6%, and firm announced ~$230M dividend plus $300M+ buybacks.
  • Vicor reports backlog growth and margin expansion, positioning it for AI power demand and potential revenue and free-cash-flow upside.
  • Brookfield priced $600M senior notes due 2031 at 5.65% to fund general corporate purposes, closing expected Sept 23.
  • Woodward will shift aerospace controls production from Santa Clarita to Spartanburg, affecting roughly 400 jobs and selling the legacy facility by FY2027.
  • Analyst initiates Buy on Cue Biopharma after a positive CUE-221 CSU readout, recommending a tactical entry and a 45-day $45 target.
  • Helus Pharma CEO to appear at the TD Cowen neuropsychiatry summit, spotlighting serotonergic agonists and FDA Breakthrough Therapy status for HLP003.

Latest Articles

First Mid Bancshares, Inc. Announces Second Quarter 2026 Results

First Mid Bancshares, Inc. Announces Second Quarter 2026 Results

First Mid Bancshares, Inc. announced strong second quarter 2026 financial results, highlighted by record quarterly earnings with net income at $27.8 million and adjusted net income at $33.4 million. The company successfully completed the merger with Two Rivers Bank & Trust, boosting net interest income and wealth management revenues. Despite additi…

iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication

iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication

Insight Molecular Diagnostics (Nasdaq: IMDX) announced the publication of a study in The Lancet Regional Health demonstrating that its GraftAssure assay, which measures donor-derived cell-free DNA (dd-cfDNA), can effectively guide treatment decisions for kidney transplant patients to manage antibody-mediated rejection (AMR). The study builds on pre…

Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea

Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea

Incannex Healthcare announced the commencement of participant screening in its Phase 2 DReAMzz trial evaluating IHL-42X for obstructive sleep apnea (OSA). The drug has FDA Fast Track designation, highlighting its potential to address the unmet need in OSA with no currently approved oral therapies. The DReAMzz study aims to optimize dosing while ass…

HomeTrust Bancshares, Inc. Announces Financial Results for the Second Quarter of the Year Ending December 31, 2026 and Declaration of a Quarterly Dividend

HomeTrust Bancshares, Inc. Announces Financial Results for the Second Quarter of the Year Ending December 31, 2026 and Declaration of a Quarterly Dividend

HomeTrust Bancshares, Inc. announced its Q2 2026 financial results, showing net income of $15.6 million down 6.8% from the prior quarter, with diluted EPS declining from $0.99 to $0.94. Despite the slight quarterly earnings decrease, the company increased its quarterly dividend by 15.4% to $0.15 per share and repurchased 153,606 shares. Loan growth…

Serve Robotics to Report Second Quarter 2026 Financial Results, Host Conference Call and Webcast on August 6

Serve Robotics to Report Second Quarter 2026 Financial Results, Host Conference Call and Webcast on August 6

Serve Robotics, a Nasdaq-listed autonomous robotics company, will report its second quarter 2026 financial results on August 6, 2026, followed by a conference call and webcast. Since its spin-off from Uber, Serve has deployed over 2,000 robots in the U.S. and expanded operations into indoor service robots with the acquisition of Diligent Robotics.

Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

Apyx Medical Corporation, a NASDAQ-listed company specializing in surgical aesthetics technologies such as Renuvion and the AYON Body Contouring System, announced it will release its second quarter fiscal year 2026 financial results after market close on August 6, 2026. Management will hold a conference call to discuss the results and answer questi…

Terra Innovatum Initiates NRC Preapplication Readiness Review to Support Solo™ Construction Permit Application

Terra Innovatum Initiates NRC Preapplication Readiness Review to Support Solo™ Construction Permit Application

Terra Innovatum Global N.V. has initiated a voluntary preapplication readiness review with the U.S. Nuclear Regulatory Commission (NRC) to support its planned 2026 Construction Permit Application for the SOLO™ Micro-Modular Reactor. This strategic step aims to allow NRC staff early review of safety and environmental draft documentation, enabling id…

WillScot to Announce Second Quarter 2026 Results on August 6, 2026 and to Present at an Upcoming Investor Conference in August

WillScot to Announce Second Quarter 2026 Results on August 6, 2026 and to Present at an Upcoming Investor Conference in August

WillScot Holdings Corporation announced it will report its Q2 2026 financial results on August 6, 2026, after market close, followed by a conference call and webcast. The company will also participate in the Deutsche Bank Chicago Industrials Summit on August 11, 2026. WillScot specializes in temporary flexible space solutions serving critical indus…

UMAC: The Run Has Begun — But This Rally Still Has Room to Run

UMAC: The Run Has Begun — But This Rally Still Has Room to Run

Unusual Machines (UMAC) has ripped higher on government-program chatter and index inclusion, pushing the stock back toward its 52-week high. Fundamentals remain early-stage and loss-making, but meaningful cash on the balance sheet, short-coverable float and active defense catalysts create a tradeable asymmetric setup. This piece lays out an actiona…

Syntec Optics (Nasdaq: OPTX) Included in Russell 3000® Index

Syntec Optics (Nasdaq: OPTX) Included in Russell 3000® Index

Syntec Optics Holdings, Inc., a leading manufacturer of high-precision optics and photonics technologies serving defense and space sectors, announced its inclusion in the Russell 3000® Index. This inclusion enhances the company's visibility to a broad range of investors and mutual funds tracking this key U.S. equity benchmark, potentially increasin…

Wesco: The Quiet Play on AI Infrastructure and Power Buildouts

Wesco: The Quiet Play on AI Infrastructure and Power Buildouts

Wesco International sits at the crossroads of several durable infrastructure trends — data center expansion, fiber and broadband rollouts, and grid modernization. At a current price of $330.58, the stock offers exposure to that capex cycle with a P/S of ~0.66 and an EV/EBITDA of 14.25. This trade idea lays out a mid-term long with defined entry, st…

Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

Nuvectis Pharma announced that its once-daily oral complement Factor B inhibitor, ciprocopan (NXP100), received marketing approval in China for treatment of PNH patients previously untreated with complement inhibitors. This approval, granted by China’s NMPA, is based on robust Phase 3 clinical data demonstrating ciprocopan’s superior efficacy and s…

FirstService Reports Second Quarter 2026 Results

FirstService Reports Second Quarter 2026 Results

FirstService Corporation reported second quarter 2026 results with a 2% increase in revenues to $1.45 billion and a 3% rise in Adjusted EBITDA to $161.7 million. Adjusted EPS rose 2% year-over-year to $1.75. The company acknowledged ongoing macroeconomic headwinds that have moderated organic growth but expects similar or slightly improved top-line …

Revolver Brewing Becomes Revolver Beer and Spirits, Extending the Blood & Honey Brand into Whiskey, Gin and Vodka

Revolver Brewing Becomes Revolver Beer and Spirits, Extending the Blood & Honey Brand into Whiskey, Gin and Vodka

Tilray Brands’ Revolver Beer and Spirits has evolved from brewing into a broader beverage company by launching the Blood & Honey Spirits line, which includes whiskey, gin, and vodka all infused with Texas honey and inspired by their iconic Blood & Honey beer. The new products debut exclusively in Texas, aiming to capture consumers looking for disti…

ZenaTech's Drone as a Service Closes 26th Acquisition of an Ohio-based Land Surveying Company Licensed in Four States

ZenaTech's Drone as a Service Closes 26th Acquisition of an Ohio-based Land Surveying Company Licensed in Four States

ZenaTech, Inc., a Nasdaq-listed AI and Drone as a Service technology company, completed its 26th acquisition by purchasing BA Land Professionals LLC, a full-service land surveying firm operating in Ohio, Kentucky, Tennessee, and North Carolina. This acquisition extends ZenaTech's DaaS network to 12 U.S. states and bolsters its presence in construct…

Streamex Corp. Details GLDY’s Liquidity Infrastructure; ~$12 Million in Seeded Liquidity Supports 24/7, 365 Instant Trading Across Multiple Institutional-Grade Venues

Streamex Corp. Details GLDY’s Liquidity Infrastructure; ~$12 Million in Seeded Liquidity Supports 24/7, 365 Instant Trading Across Multiple Institutional-Grade Venues

Streamex Corp. (NASDAQ: STEX) announced a comprehensive liquidity infrastructure supporting GLDY, its gold-backed, yield-bearing tokenized asset. The company implemented three independent liquidity venues—Wintermute Instant Liquidity Facility, Orca decentralized liquidity pools, and the SEC-registered tZERO ATS—to enable investors to buy or sell GL…

Autonomix Medical Secures New U.S. Patent Strengthening Next-Generation Precision Neuromodulation Platform

Autonomix Medical Secures New U.S. Patent Strengthening Next-Generation Precision Neuromodulation Platform

Autonomix Medical, Inc. has been granted U.S. Patent No. 12,471,776, which broadly covers systems and methods for monitoring autonomic nervous system activity. This enhances their intellectual property portfolio supporting their precision nerve-targeted treatment platform. The patent covers technologies designed for improved patient selection, trea…